Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 4/20 | 0.66 |
| ▸ | PIM1 | P11309 | 9/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224451 | 1.00 | NAT1 (0.66) | NAT1PIM1CA2EPHX1PTP4A3 | |
| SCHEMBL13243991 | 0.86 | PIM1 (0.59) | NAT1PIM1 | |
| SCHEMBL1243983 | 0.82 | PIM1 (0.55) | NAT1PIM1CA2EPHX1PTP4A3 | |
| SCHEMBL1243984 | 0.82 | PIM1 (0.55) | NAT1PIM1CA2EPHX1PTP4A3 | |
| SCHEMBL1243980 | 0.82 | PIM1 (0.55) | NAT1PIM1CA2EPHX1PTP4A3 | |
| SCHEMBL1247510 | 0.80 | NAT1 (1.00) | NAT1PIM1CA2EPHX1MEN1 | |
| SCHEMBL10596480 | 0.80 | NAT1 (1.00) | NAT1PIM1CA2EPHX1MEN1 | |
| SCHEMBL1247509 | 0.80 | NAT1 (1.00) | NAT1PIM1CA2EPHX1MEN1 | |
| SCHEMBL18102962 | 0.79 | NAT1 (0.76) | NAT1PIM1CA2EPHX1MEN1 | |
| SCHEMBL19991267 | 0.79 | NAT1 (0.76) | NAT1PIM1CA2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | NAT1 299/4885PIM1 4317/4885CA2 1856/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | NAT1 299/4885PIM1 4317/4885CA2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.